Clinical Trial Update: BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study of BGB-290 in combination with temozolomide in patients with recurrent gliomas harboring IDH1/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Glioma
• Glioblastoma
• Low-grade Glioma

Drugs mentioned

• BGB-290
• Temozolomide (Temozolomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: IDH1 Mutation, IDH2 Mutation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-16